Leap Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Cypherpunk Technologies Inc. filed its Q2 2026 10-Q, detailing a shift towards a digital asset treasury strategy alongside its ongoing biopharmaceutical research, marked by a substantial unrealized gain on digital assets but also significant operating losses.
Cypherpunk Technologies Inc. reported its first quarter 2026 financial results, highlighting a significant shift towards a digital asset treasury strategy alongside its ongoing biotechnology operations.
Cypherpunk Technologies Inc. (formerly Leap Therapeutics) has completed a strategic pivot to a digital asset treasury strategy focused on Zcash, raising $58.8 million and appointing new digital asset-focused executives.
Leap Therapeutics reported a significant cash burn and workforce reduction, raising substantial doubt about its ability to continue as a going concern while exploring strategic alternatives.
Leap Therapeutics announces Q1 2025 financial results, provides updates on its clinical programs, and unveils a strategic restructuring to prioritize sirexatamab development in colorectal cancer (CRC).
Leap Therapeutics reported a net loss of $18.2 million for the third quarter of 2024, while continuing to advance its clinical programs.
Leap Therapeutics reported its second quarter 2024 financial results, highlighting progress in clinical trials and a recent $40 million private placement.
Leap Therapeutics reported a net loss of $13.8 million for the first quarter of 2024, while also highlighting clinical trial progress and a recent $37.2 million private placement.